Rita Nanda

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
    Rita Nanda
    Rita Nanda, University of Chicago, Chicago, IL Laura Q M Chow, University of Washington, Seattle, WA E Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC Raanan Berger, Sheba Medical Center, Tel Hashomer Ravit Geva, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Shilpa Gupta, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Lajos Pusztai, Yale University School of Medicine, New Haven, CT Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng, and Vassiliki Karantza, Merck and Co, Kenilworth, NJ and Laurence Buisseret, Universite Libre de Bruxelles, Bruxelles, Belgium
    J Clin Oncol 34:2460-7. 2016
  2. doi request reprint "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers
    Rita Nanda
    Department of Medicine, The University of Chicago, Chicago, IL 60637 1470, USA
    Semin Oncol 38:254-62. 2011
  3. ncbi request reprint Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions
    Rita Nanda
    Section of Hematology Oncology, Department of Medicine, University of Chicago, USA
    Rev Recent Clin Trials 2:111-6. 2007
  4. pmc Advances in breast cancer: pathways to personalized medicine
    Olufunmilayo I Olopade
    Department of Medicine, Section of Hematology Oncology, Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 14:7988-99. 2008
  5. pmc Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer
    Dezheng Huo
    Center for Clinical Cancer Genetics and Global Health, Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 27:4515-21. 2009
  6. pmc Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers
    Minjie Wei
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637 1463, USA
    Breast Cancer Res Treat 111:113-20. 2008
  7. pmc The role of tumor-associated macrophages in breast cancer progression (review)
    Elias Obeid
    Section of Hematology Medical and Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 43:5-12. 2013
  8. pmc Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
    Nancy U Lin
    Nancy U Lin, Hao Guo, Nicole Ryabin, Julie S Najita, William T Barry, Ian E Krop, Eric P Winer, and Annick D Van den Abbeele, Dana Farber Cancer Institute Andrea L Richardson and Annick D Van den Abbeele, Brigham and Women s Hospital, Boston, MA Jeffrey T Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Ingrid A Mayer and Carlos L Arteaga, Vanderbilt Ingram Cancer Center, Nashville, TN Carla I Falkson, University of Alabama, Birmingham, AL Timothy J Hobday, Mayo Clinic, Rochester, MN E Claire Dees, University of North Carolina, Chapel Hill, NC Rita Nanda, University of Chicago, Chicago, IL Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX and Antonio C Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
    J Clin Oncol 33:2623-31. 2015
  9. pmc A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
    Rita Nanda
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 USA 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470 USA
    Springerplus 5:947. 2016
  10. pmc The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006

Collaborators

Detail Information

Publications14

  1. doi request reprint Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
    Rita Nanda
    Rita Nanda, University of Chicago, Chicago, IL Laura Q M Chow, University of Washington, Seattle, WA E Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC Raanan Berger, Sheba Medical Center, Tel Hashomer Ravit Geva, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Shilpa Gupta, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Lajos Pusztai, Yale University School of Medicine, New Haven, CT Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng, and Vassiliki Karantza, Merck and Co, Kenilworth, NJ and Laurence Buisseret, Universite Libre de Bruxelles, Bruxelles, Belgium
    J Clin Oncol 34:2460-7. 2016
    ..We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC...
  2. doi request reprint "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers
    Rita Nanda
    Department of Medicine, The University of Chicago, Chicago, IL 60637 1470, USA
    Semin Oncol 38:254-62. 2011
    ..This review focuses on our current understanding of the clinicopathological features of TNBC, therapeutic options and ongoing research efforts...
  3. ncbi request reprint Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions
    Rita Nanda
    Section of Hematology Oncology, Department of Medicine, University of Chicago, USA
    Rev Recent Clin Trials 2:111-6. 2007
    ....
  4. pmc Advances in breast cancer: pathways to personalized medicine
    Olufunmilayo I Olopade
    Department of Medicine, Section of Hematology Oncology, Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 14:7988-99. 2008
    ..The five articles in this edition of CCR Focus highlight recent advances and future directions on the pathway to individualized approaches for the early detection, treatment, and prevention of breast cancer...
  5. pmc Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer
    Dezheng Huo
    Center for Clinical Cancer Genetics and Global Health, Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 27:4515-21. 2009
    ..In the first study of its kind, we determined the distribution of molecular subtypes of invasive breast tumors in indigenous black women in West Africa...
  6. pmc Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers
    Minjie Wei
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637 1463, USA
    Breast Cancer Res Treat 111:113-20. 2008
    ..These data suggest that unlike FANCF, both ER and BRCA1 are specifically targeted for methylation in sporadic breast cancers, a phenomenon that should be explored for development of novel diagnostic and therapeutic approaches...
  7. pmc The role of tumor-associated macrophages in breast cancer progression (review)
    Elias Obeid
    Section of Hematology Medical and Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 43:5-12. 2013
    ..Given the multiple roles of TAMS in breast cancer progression and metastasis, therapies targeting these cells are in development and demonstrate promising results...
  8. pmc Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
    Nancy U Lin
    Nancy U Lin, Hao Guo, Nicole Ryabin, Julie S Najita, William T Barry, Ian E Krop, Eric P Winer, and Annick D Van den Abbeele, Dana Farber Cancer Institute Andrea L Richardson and Annick D Van den Abbeele, Brigham and Women s Hospital, Boston, MA Jeffrey T Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Ingrid A Mayer and Carlos L Arteaga, Vanderbilt Ingram Cancer Center, Nashville, TN Carla I Falkson, University of Alabama, Birmingham, AL Timothy J Hobday, Mayo Clinic, Rochester, MN E Claire Dees, University of North Carolina, Chapel Hill, NC Rita Nanda, University of Chicago, Chicago, IL Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX and Antonio C Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
    J Clin Oncol 33:2623-31. 2015
    ..We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes...
  9. pmc A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
    Rita Nanda
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 USA 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470 USA
    Springerplus 5:947. 2016
    ..GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical trial of mifepristone and nab-paclitaxel in advanced breast cancer...
  10. pmc The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
    ..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
  11. ncbi request reprint Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
    Chad A Livasy
    Department of Pathology and Lab Medicine, University of North Carolina, Chapel Hill, NC 27599 7525, USA
    Mod Pathol 19:264-71. 2006
    ..These findings should further assist in the identification of basal-like carcinomas in clinical specimens, facilitating treatment and epidemiologic studies of this tumor subtype...
  12. ncbi request reprint BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy
    Minjie Wei
    Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago, Chicago, Illinois 60637 1463, USA
    Cancer Res 65:10692-9. 2005
    ..Our data support a model of carcinogenesis in which BRCA1 promoter methylation may serve as a "first hit," much like an inherited germ line mutation, and promote tumor progression down a restricted set of molecular pathways...
  13. ncbi request reprint Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry
    Rita Nanda
    Center for Clinical Cancer Genetics, Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Ill 60637 1470, USA
    JAMA 294:1925-33. 2005
    ..Ten years after BRCA1 and BRCA2 were first identified as major breast cancer susceptibility genes, the spectrum of mutations and modifiers of risk among many ethnic minorities remain undefined...
  14. pmc A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies
    David S Shames
    Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
    PLoS Med 3:e486. 2006
    ....